Stock Market Reviews

GLUE (Monte Rosa Therapeutics, Inc.) News

Get the latest news, insights, and market updates on GLUE (Monte Rosa Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
  NeoGenomics (NEO) delivered earnings and revenue surprises of +57.90% and +0.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Feb 17, 2026 - $GLUE
• Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains
  Key Insights Significantly high institutional ownership implies Monte Rosa Therapeutics' stock price is sensitive to...
  Feb 6, 2026 - $GLUE
• Staar Surgical, Alumis, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Jan 17, 2026 - $GLUE
• Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum
  Monte Rosa Therapeutics (GLUE) drew fresh attention after reporting strong interim Phase 1 results for MRT-8102, its NEK7-directed molecular glue degrader. The data showed rapid, sustained reductions in inflammatory markers in subjects with elevated cardiovascular risk and a favorable safety profile. See our latest analysis for Monte Rosa Therapeutics. That clinical update has arrived during a period of sharp price swings, with a 7 day share price return of 58.59% and a 90 day share price...
  Jan 10, 2026 - $GLUE
• Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
  BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price
  Jan 9, 2026 - $GLUE
• Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
  Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
  Jan 8, 2026 - $GLUE
• GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
  Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
  Jan 8, 2026 - $GLUE
• Top Midday Gainers
  Monte Rosa Therapeutics (GLUE) said Wednesday early trial results of its drug candidate, MRT-8102, s
  Jan 7, 2026 - $GLUE
• Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why
  Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Jan 7, 2026 - $GLUE
• Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
  BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase
  Jan 7, 2026 - $GLUE